HPV VACCINATION BEST PRACTICES LEARNING COLLABORATIVE
BACKGROUND

AMGA and the National HPV Vaccination Roundtable are launching an 18-month learning collaborative to improve HPV vaccination rates among adolescents served by medical groups and integrated health systems. This Collaborative is based on the successful work undertaken in AMGA’s Adult Immunization Best Practices Learning Collaborative. Eight health care organizations will be recruited to implement best practice interventions and strategies. Funding was made possible by the Centers for Disease Control and Prevention under CFDA # 93.421 – Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health, Cooperative Agreement grant number 6 NU38OT000283-02-01.

BENEFITS

The Collaborative will create a community of knowledge to accelerate systematic change and develop care processes to improve HPV vaccination among adolescent patients. Through the Collaborative, organizations that want to be on the leading edge of adolescent population health management have the opportunity to team with other engaged organizations in a national forum.

The objective of this program is to develop and implement evidence-based strategies and interventions to improve HPV vaccination rates in multi-specialty medical groups or integrated health systems with a focus on adolescents. Collaborative members will be part of an elite group with unique access to national leaders and organizations at in-person events and during online webinars. The HPV Roundtable will provide resources to raise HPV vaccination rates in health systems. The AMGA team will make site visits to assist organizations with adapting and implementing interventions and to assist with translating emergent best practices across participants. Each participating organization will receive an $8,000 honorarium. Travel and meeting costs will be reimbursed separately.

WHAT WE ALREADY KNOW

Fourteen million Americans acquire HPV infections each year. We do not know which infections will clear and which infections will not. We do know that the HPV vaccine covers strains that cause over 90% of HPV cancers, mitigating patient risk. Approximately 92 people each day are diagnosed with an HPV-attributable cancer. These patients and their families face the emotional impact of a cancer diagnosis, the challenges of cancer treatment, and the possibility of death. Health systems with missions to improve health, provide high quality care, and serve their communities have been caring for these patients as well as managing the high financial costs that accompany cancer care. Health systems are well positioned to expedite HPV vaccine uptake and help eliminate HPV cancers.

APPROACH

The Collaborative will create a community of knowledge that will help participants accelerate systematic change and develop care processes to address HPV vaccinations. Participating groups will create multi-disciplinary project teams. Groups must obtain high-level organizational leadership buy-in and sign-off on the Collaborative.

HOW DOES THE COLLABORATIVE WORK?

Participating organizations will regularly meet with peers and experts through:

- Two in-person meetings: February 2020 (kick-off) January 2021 (wrap-up)
- Every other month webinars
- Online resources – a dedicated website for Collaborative participant material sharing and a listserv for idea sharing and collaboration
- Consultation in the field from AMGA, National HPV Vaccination Roundtable, and external experts
PROJECT TIMELINE

<table>
<thead>
<tr>
<th>ACTIVITIES</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV Collaborative Call for Participation Distributed</td>
<td>October 1, 2019</td>
</tr>
<tr>
<td>Applications due to AMGA Foundation</td>
<td>October 31, 2019</td>
</tr>
<tr>
<td>Applicants notified</td>
<td>November 8 – 11, 2019</td>
</tr>
<tr>
<td>Getting Started Checklist Calls with participating organizations</td>
<td>November 2019</td>
</tr>
<tr>
<td>Memorandum of Understanding (MOU) due from participating organizations</td>
<td>December 2, 2019</td>
</tr>
<tr>
<td>Orientation and Data Webinar</td>
<td>December 11, 2019 9:30 – 11 A.M. ET</td>
</tr>
<tr>
<td>Collaborative Kick-off Meeting, Atlanta, GA</td>
<td>February 24 – 26, 2020</td>
</tr>
<tr>
<td>Every other month webinars</td>
<td>March – November 2020</td>
</tr>
<tr>
<td>Site visit with AMGA</td>
<td>September – October 2020</td>
</tr>
<tr>
<td>Collaborative Wrap-up Meeting, Atlanta, GA Date TBD</td>
<td>January 2021</td>
</tr>
</tbody>
</table>

ADVISORY COMMITTEE

AMGA Foundation selected a team of experts to guide us through this program. Advisors include:

- **Kara Elam, Ph.D., M.P.H., M.S.**
  ORISE Fellow in Vaccine Policy, Office of Infectious Disease & HIV/AIDS Policy (OIDP), U.S. Department of Health & Human Services

- **Melissa Gilkey, Ph.D.**
  Assistant Professor, Department of Health Behavior, University of North Carolina’s Gillings School of Global Public Health

- **Sarah Kobrin, Ph.D., M.P.H.**
  Chief of Health Systems & Interventions Research Branch, National Cancer Institute

- **Jason Maxwell, M.D.**
  Department Chair for Pediatrics and Practices, HealthPartners Como Clinic

- **Kristin Oliver, M.D., M.H.S.**
  Assistant Professor, Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, Department of Pediatrics

- **Andrea Polkinghorn, BSN, RN-BC**
  Immunization Strategy Leader, Sanford Health

- **Melinda Wharton, M.D.**
  Director, Immunization Services Division, NCIRD, Centers for Disease Control and Prevention

APPLY TODAY!

[www.amga.org/hpv](http://www.amga.org/hpv)

CONSIDERATIONS BEFORE APPLYING

- Your organization must be a current member of AMGA and must sustain its membership throughout the Collaborative.
  - One Tax I.D. per group (per AMGA membership status)
- Potential members of AMGA are encouraged to contact Jessica Prior at [jprior@amga.org](mailto:jprior@amga.org) for more information about becoming an AMGA member.
- Medical groups, IPAs, academic practices, and integrated delivery systems that wish to optimize the management of HPV vaccinations are encouraged to submit an application.
CRITERIA FOR PARTICIPATION

This funding focuses on improving adolescent HPV vaccination rates of uptake and series completion. We encourage organizations with sizeable populations of adolescents (primary care, 9-12 and 13-17 years) to apply. Participating organizations must sign an agreement outlining the Collaborative expectations below for the duration of the project:

- Create a project team
  - Must include an employed or clinically-integrated affiliated provider and/or clinical champion as an identified team lead/champion who has dedication to this project and an interest in HPV vaccinations.
    - Suggested team members include: physician champion, advanced practice clinicians, nurses, medical assistants, pharmacists, social worker, care manager, quality improvement specialists, data/IT analyst, revenue services manager, etc.
    - At least 4 team members are encouraged to participate in all Collaborative activities; 2 team members are required to attend the two in-person meetings (reasonable travel costs will be reimbursed); groups may send an additional 1-2 team members if they cover their travel expenses.
  - Must have a commitment for expected resources
    - Obtain high-level organizational leadership buy-in and sign-off on the project and anticipated or budgeted resources
- Must have a process for workflow standardization and documentation of vaccinations
- Report quarterly in 2020 on the following measures* (note: these are proposed draft measures and will be refined under the guidance of the Advisors before the launch of the Collaborative):
  - HPV Vaccination Initiation and Completion Rates, stratified by age and sex
  - Meningococcal Vaccination Rates, stratified by age and sex (for comparison)
  - Tdap Vaccination Rates, stratified by age and sex (for comparison)

*Draft measurement specifications are provided to ensure consistent reporting across all participating groups. Specifications can be found at www.amga.org/hpv

- Ability to report on required measures including a baseline period, e.g., quarterly, FY2019, CY2018
- Submit periodic updates/action plans
- Host AMGA staff for one onsite visit
- Participate in webinars and two in-person meetings
- Acknowledge that AMGA and the National HPV Vaccination Roundtable may author a summary publication on the learning collaborative results

EVALUATION CRITERIA

Applications will be evaluated with respect to:

<table>
<thead>
<tr>
<th>COMMITTED RESOURCES</th>
<th>POTENTIAL IMPACT</th>
<th>SUSTAINABILITY INTENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ability to dedicate people and financial resources to the project</td>
<td>Number of adolescent patients impacted (due to population size, region, demographics, and current vaccination rates)</td>
<td>Organizational commitment to sustain progress beyond funding period</td>
</tr>
<tr>
<td>IT plan to submit data on specific measures and the ability to identify targeted populations</td>
<td>Focus on innovation and quality improvement</td>
<td>Tracking and performance monitoring to ensure ongoing effectiveness</td>
</tr>
<tr>
<td>Creation of a dedicated project team (as identified above)</td>
<td>Feasibility and scalability</td>
<td></td>
</tr>
</tbody>
</table>

www.amga.org/hpvroundtable.org
INSTRUCTIONS FOR PREPARING YOUR APPLICATION
— APPLICATIONS ARE DUE BY CLOSE OF BUSINESS (5:30 P.M. PT), OCTOBER 31, 2019 —

STEP 1
Complete the HPV Collaborative Application Template provided on www.amga.org/hpv. Please provide no more than a total of 6 pages. (Font Specifications: Calibri or Arial, 11 point)
- Include an organizational profile that gives advisors an understanding of the size and scope of your organization without revealing the identity of your organization.
- Provide answers for each of the 9 sections.

STEP 2
Applications will be evaluated in a blinded review process. Remove all patient, provider, and clinic identifiers from the application except for the cover sheet with the contact information.
- Refer to people by title (not name).
- Refer to your organization using words like “medical group” or “organization” (recommend using the Word search and replace function to make sure your organization name and acronym do not appear in the document).
- Please identify your organization state in the application.

STEP 3
Complete the provided cover sheet template and include:
- Organization name
- Project title
- Primary Contact Information (name, title, e-mail, phone, address)
- Information Technology Contact Information (name, title, e-mail, phone, address)
- Physician Champion Contact Information (name, title, e-mail, phone, address)
- Sponsor signature (CEO, medical director, department head) and contact information (name, title, e-mail, phone, address)

STEP 4
Provide supporting information:
You are welcome to cite and label the supporting documents in an appendix. It is highly preferred that supporting documents are clearly labeled as “Appendix 1,” “Appendix 2,” etc. (Note: Remove all patient, provider, clinic identifiers, and logos) Maximum 5 pages.

STEP 5
Submit one electronic copy of the application to hpv@amga.org by close of business (5:30 P.M. PT), October 31, 2019.

QUESTIONS OR COMMENTS?
If you have questions or need further information, contact Erin Leaver-Schmidt at eleaver-schmidt@amga.org or by phone at (703) 838-0033, ext. 390 or visit our website at www.amga.org/hpv.